Fianlimab and cemiplimab in patients with advanced melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from a subgroup analysis of a Phase I trial (NCT03005782) of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, and cemiplimab in patients with advanced melanoma. In two cohorts of 80 patients who were anti-PD-(L)1 naïve, 19 patients had liver metastases and 28 had elevated lactate dehydrogenase levels. A favorable overall response rate and disease control rate were reported. Fianlimab and cemiplimab additionally were well tolerated, with only two patients reporting a grade 5 adverse event. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.